Researchers from Stanford developed chemically modified adeno-associated virus (AAV) capsids that enable selective gene delivery to either exocrine or endocrine pancreatic cells through unnatural amino acid incorporation and peptide conjugation.
Stanford researchers have discovered that Neat1, a long non-coding RNA, regulates degradation of the MYC protein, revealing a new target for treating MYC-dependent cancers.
Stanford researchers have developed chemically modified AAV vectors through an unnatural amino acid substitution on the capsid surface for post-production vector engineering through biorthogonal copper-free click chemistry.
Researchers at Stanford University have discovered that the absence of a long non coding RNA (lnc122) predisposed mice to high numbers of hepatocellular carcinomas (HCC), and its replacement decreased the risk of HCC.
Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford inventors have engineered an adeno-associated virus (AAV) variant on the existing LK03 platform that enables this highly efficient primate-specific serotype for use in rodent preclinical studies.
Researchers in Dr. Mark Kay's lab have developed a patented approach to inducing apoptosis that could represent a new strategy against cancer and other diseases.
Stanford researchers developed a single plasmid reprogramming system called CoMiP carrying codon optimized sequences of the canonical reprogramming factors (OKSM) and short hairpin RNA against p53.
Dr. Mark Kay and colleagues have created antibiotic-selectable, non-silencing plasmid vectors that can be prepared by conventional methods and provide persistent high levels of transgene expression.
Researchers in Prof. Mark Kay's laboratory have continued to develop novel recombinant adeno-associated viral (AAV) capsids via capsid gene shuffling that transduce human hepatocytes at high efficiency in vivo.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.
Researchers from Dr. Mark Kay's laboratory at Stanford University have merged desirable qualities of multiple natural AAV isolates by an adapted DNA family shuffling technology to create a complex library of hybrid capsids from eight different wild-type viruses.
Researchers in Prof. Mark Kay's laboratory have developed a robust vector that combines the ease of plasmid preparation with the stable expression achieved by minicircle vectors.
The minicircle is a non-viral DNA vector for non-insertional transgene expression. A typical minicircle contains a transgene expression cassette, and is free of all other plasmid DNA elements, including an antibiotic resistance gene and a plasmid DNA replication origin.
A team of Stanford researchers have developed a simple, novel, non-viral technique for generating human induced pluripotent stem cells (hiPSCs) with minicircle DNA. This technology uses a single minicircle vector that expresses four reprogramming factors.